Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution

Petit, A.; Floquet, Anne; Lasbareilles, O.; Stoeckle, Eberhard; Chemin, A.; Kind, Michèle; Guyon, Frédéric; Brouste, Véronique; Pigneux, J; Thomas, Laurence

doi:10.1016/j.brachy.2013.05.003

Cited by 12 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seeger et al 69 included Gy after EBRT in all types of gynaecological tumours. LC of 53% was lower than that of the more recent studies, [10][11][12]65 with GI, GU and gynaecological Grade 3 toxicity approximately 15%.…”

Section: Sarcomas Of the Extremitiescontrasting

confidence: 63%

See 1 more Smart Citation

A review of the clinical experience in pulsed dose rate brachytherapy

Balgobind

Koedooder

Zúñiga

et al. 2015

BJR

View full text Add to dashboard Cite

Pulsed dose rate (PDR) brachytherapy is a treatment modality that combines physical advantages of high dose rate (HDR) brachytherapy with the radiobiological advantages of low dose rate brachytherapy. The aim of this review was to describe the effective clinical use of PDR brachytherapy worldwide in different tumour locations. We found 66 articles reporting on clinical PDR brachytherapy including the treatment procedure and outcome. Moreover, PDR brachytherapy has been applied in almost all tumour sites for which brachytherapy is indicated and with good local control and low toxicity. The main advantage of PDR is, because of the small pulse sizes used, the ability to spare normal tissue. In certain cases, HDR resembles PDR brachytherapy by the use of multifractionated low-fraction dose.

show abstract

Section: Sarcomas Of the Extremitiescontrasting

confidence: 63%

“…[9][10][11][12][13][14][15][16][17][18][19] Articles were published between 1997 and 2013 and mostly 9 reported data only for a subset of patients for whom optimization was performed on CT scan or MRI. In all studies, intracavitary PDR was performed with a tandem and ovoids, but occasionally a mould was used in the STIC-PDR study.…”

Section: Resultsmentioning

confidence: 99%

A review of the clinical experience in pulsed dose rate brachytherapy

Balgobind

Koedooder

Zúñiga

et al. 2015

BJR

View full text Add to dashboard Cite

show abstract

“…Brachytherapy, a commonly applied therapeutic modality in the treatment of gynaecological [1][2][3] and prostate cancer [4], is continuously gaining more acceptance as a method expanding the role of conventional percutaneous radiotherapy in the treatment of head and neck cancer [5,6]. Its range of application includes primary disease, recurrences and residual tumour.…”

Section: Introductionmentioning

confidence: 99%

Customized individual applicators for endocavitary brachytherapy in patients with cancers of the nasal cavity, sinonasal region and nasopharynx

Kadah

Niewald

Papaspyrou

et al. 2015

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Brachytherapy has become an established therapeutic regimen for primary, persistent, recurrent and metastatic tumour disease in the head and neck region. This study presents the authors' preliminary experience with intracavitary brachytherapy by means of an individual silicone applicator in the treatment of patients with nasal, sinonasal, orbital and nasopharyngeal cancer. Between January 2001 and January 2013, twenty patients with cancer of the nasal cavity, the paranasal sinuses and nasopharynx underwent surgery and intracavitary brachytherapy with the aid of an individually manufactured silicone applicator in the Department of Otolaryngology, Head and Neck Surgery and in the Department of Radiotherapy and Radiooncology at the Saarland University Medical Center of Homburg, Germany. The tumour was localized in the nasal cavity/paranasal sinuses (15) affecting the orbit twice and the nasopharynx (5). There were 14 patients with squamous cell carcinoma, 2 patients with mixed tumours and one patient with adenocarcinoma, adenoid cystic carcinoma, mucosal melanoma or plasmocytoma. The majority of the patients presented with advanced disease (T3 or T4 tumours). In 18/20 patients, brachytherapy was performed as a boost technique, in the remaining two solely because of a previous radiation series. All surgical interventions were performed endonasally. Three to six weeks after surgery, a cast of the nasal cavity was created under general anaesthesia. Subsequently, an individual brachytherapy silicon applicator with two to four plastic tubes was manufactured. The radiation therapy was applied using the Ir-192 high-dose-rate-afterloading method (total dose 10-20 Gy) in two to five sessions, additionally in 18/20 patients a percutaneous radiotherapy with a total dose of 30-60 Gy was applied. After a mean duration of follow-up of 2 years, 7/20 patients experienced a local progression, 5/19 a regional recurrence in the neck nodes and 4/19 distant metastases. The 2-year survival was 57.3 %. No serious complications were reported. The silicone applicator was well tolerated by all patients. Because of the complexity of the sinonasal anatomy with the finding of mainly advanced tumours, the presented individual silicone brachytherapy applicator has proven to be useful and meaningful for endocavitary brachytherapy of malignancies of the nasal cavities, paranasal sinuses and nasopharynx.

show abstract

“…The advent of image‐guided adaptive brachytherapy (IGABT) over the last decade has resulted in a pjmirodigm shift in the treatment approach to cervix cancer from point‐based dosimetry to volume‐based dosimetry. This has resulted in significant improvements to local control and reduced toxicity, Table . Previous reports have demonstrated that centres in Australia are adopting image‐guided protocols with an increase in the use of 3D imaging in brachytherapy planning from 27% in 2005 to 65% in 2009 .…”

Section: Introductionmentioning

confidence: 99%

“…This has resulted in significant improvements to local control and reduced toxicity, Table 1. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] Previous reports have demonstrated that centres in Australia are adopting image-guided protocols with an increase in the use of 3D imaging in brachytherapy planning from 27% in 2005 to 65% in 2009. 17,18 The purpose of this survey was to explore the current patterns of practice for brachytherapy in cervix cancer in Australia and New Zealand.…”

Section: Introductionmentioning

confidence: 99%

Patterns of practice survey for brachytherapy for cervix cancer in Australia and New Zealand

et al. 2017

View full text Add to dashboard Cite

Brachytherapy remains an integral component of definitive treatment for cervix cancer in Australia and New Zealand. There was increased use of soft tissue imaging modalities with emphasis on verification; high rates of volumetric planning, and adherence to a defined overall treatment period. Brachytherapy was not substituted with other EBRT modalities. Despite this, there remain barriers to implementation of image-guided brachytherapy.

show abstract

Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution

Abstract: This study demonstrates excellent LC rates with few late side effects with PDR BT for cervix carcinoma, similar to those reported in the literature with historical standard low-dose-rate BT.

Cited by 12 publications

References 32 publications

A review of the clinical experience in pulsed dose rate brachytherapy

A review of the clinical experience in pulsed dose rate brachytherapy

Customized individual applicators for endocavitary brachytherapy in patients with cancers of the nasal cavity, sinonasal region and nasopharynx

Patterns of practice survey for brachytherapy for cervix cancer in Australia and New Zealand

Contact Info

Product

Resources

About